Exposure to HIV-protease inhibitors selects for increased expression of P-glycoprotein (ABCB1) in Kaposi's sarcoma cells

British Journal of Cancer

Volumn 105, Issue 4, 2011, Pages 513-522

  Lucia, M B ^a,b   Anu, R ^a   Handley, M ^a   Gillet, J P ^a   Wu, C P ^a,c   De Donatis, G M ^a   Cauda, R ^b   Gottesman, M M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CATHOLIC UNIVERSITY   (Italy)

^c CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

ABCB1; HIV protease inhibitors; Kaposi's sarcoma; multidrug resistance; P glycoprotein

Indexed keywords

ATAZANAVIR; DOXORUBICIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INDINAVIR; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; NELFINAVIR; PACLITAXEL; RITONAVIR;

ARTICLE; CROSS RESISTANCE; DRUG EXPOSURE; DRUG POTENTIATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KAPOSI SARCOMA; LONG TERM CARE; PHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SARCOMA CELL; WESTERN BLOTTING;

ANTIBIOTICS, ANTINEOPLASTIC; BLOTTING, WESTERN; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; INDINAVIR; NELFINAVIR; OLIGOPEPTIDES; P-GLYCOPROTEIN; PYRIDINES; PYRIMIDINONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RITONAVIR; SARCOMA, KAPOSI; TREATMENT OUTCOME;

EID: 80051580324     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.275     Document Type: Article

References (49)

1. Aleman C, Annereau JP, Liang XJ, Cardarelli CO, Taylor B, Yin JJ, Aszalos A, Gottesman MM (2003) P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential. Cancer Res 63: 3084-3091 (Pubitemid 36735857)
2. Antoniou T, Tseng AL (2005) Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 44: 111-145 (Pubitemid 40188937)
3. Bao L, Haque A, Jackson K, Hazari S, Moroz K, Jetly R, Dash S (2011) Increased expression of P-glycoprotein is associated with doxorubicin chemoresistance in the metastatic 4T1 breast cancer model. Am J Pathol 178: 838-852
4. Bernstein WB, Dennis PA (2008) Repositioning HIV protease inhibitors as cancer therapeutics. Curr Opin HIV AIDS 3: 666-675
5. Bierman WF, Scheffer GL, Schoonderwoerd A, Jansen G, van Agtmael MA, Danner SA, Scheper RJ (2010) Protease inhibitors atazanavir, lopinavir and ritonavir are potent blockers, but poor substrates, of ABC transporters in a broad panel of ABC transporter-overexpressing cell lines. J Antimicrob Chemother 65: 1672-1680
6. Boshoff C, Weiss R (2002) AIDS-related malignancies. Nat Rev Cancer 2: 373-382 (Pubitemid 37328950)
7. Bower M, Collins S, Cottrill C, Cwynarski K, Montoto S, Nelson M, Nwokolo N, Powles T, Stebbing J, Wales N, Webb A (2008) British HIV Association guidelines for HIV-associated malignancies 2008. HIV Med 9: 336-388 (Pubitemid 352015641)
8. Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG (2008) Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 26: 2699-2706
9. Callaghan R, Crowley E, Potter S, Kerr ID (2008) P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 48: 365-378
10. Chaisuparat R, Hu J, Jham BC, Knight ZA, Shokat KM, Montaner S (2008) Dual inhibition of PI3Kalpha and mTOR as an alternative treatment for Kaposi's sarcoma. Cancer Res 68: 8361-8368
11. Chow WA, Jiang C, Guan M (2009) Anti-HIV drugs for cancer therapeutics: back to the future? Lancet Oncol 10: 61-71
12. Cvetkovic RS, Goa KL (2003) Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 63: 769-802 (Pubitemid 36432083)
13. Dhillon T, Stebbing J, Bower M (2005) Paclitaxel for AIDS-associated Kaposi's sarcoma. Expert Rev Anticancer Ther 5: 215-219 (Pubitemid 40553088)
14. Dittmer DP, Krown SE (2007) Targeted therapy for Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus. Curr Opin Oncol 19: 452-457 (Pubitemid 47356601)
15. Dupuis ML, Flego M, Molinari A, Cianfriglia M (2003a) Saquinavir induces stable and functional expression of the multidrug transporter P-glycoprotein in human CD4 T-lymphoblastoid CEMrev cells. HIV Med 4: 338-345 (Pubitemid 37304375)
16. Dupuis ML, Tombesi M, Cianfriglia M (2002) Modulation of the multidrug resistance (MDR) phenotype in CEM MDR cells simultaneously exposed to anti HIV-1 protease inhibitors (PI's) and cytotoxic drugs. Ann Ist Super Sanita 38: 387-392 (Pubitemid 36402432)
17. Dupuis ML, Tombesi M, Sabatini M, Cianfriglia M (2003b) Differential effect of HIV-1 protease inhibitors on P-glycoprotein function in multidrug-resistant variants of the human CD4+ T lymphoblastoid CEM cell line. Chemotherapy 49: 8-16 (Pubitemid 36469789)
18. Dussault I, Lin M, Hollister K, Wang EH, Synold TW, Forman BM (2001) Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem 276: 33309-33312
19. Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH (2002) Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi's sarcoma: an AIDS Clinical Trials Group clinical study. J Clin Oncol 20: 3236-3241 (Pubitemid 34831520)
20. Fitzgerald JB, Schoeberl B, Nielsen UB, Sorger PK (2006) Systems biology and combination therapy in the quest for clinical efficacy. Nat Chem Biol 2: 458-466 (Pubitemid 44266307)
21. Foxwell BM, Mackie A, Ling V, Ryffel B (1989) Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 36: 543-546 (Pubitemid 19273829)
22. Garcia MG, Alaniz LD, Cordo Russo RI, Alvarez E, Hajos SE (2009) PI3K/Akt inhibition modulates multidrug resistance and activates NF-kappaB in murine lymphoma cell lines. Leuk Res 33: 288-296
23. Gottesman MM, Fojo T, Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2: 48-58 (Pubitemid 37328807)
24. Granzotto M, Drigo I, Candussio L, Rosati A, Bartoli F, Giraldi T, Decorti G (2004) Rifampicin and verapamil induce the expression of P-glyco-protein in vivo in Ehrlich ascites tumor cells. Cancer Lett 205: 107-115 (Pubitemid 38230145)
25. Gupta AK, Li B, Cerniglia GJ, Ahmed MS, Hahn SM, Maity A (2007) The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response. Neoplasia 9: 271-278 (Pubitemid 46608294)
26. Gupta S, Aggarwal S, Nakamura S (1998) A possible role of multidrug resistance-associated protein (MRP) in basic fibroblast growth factor secretion by AIDS-associated Kaposi's sarcoma cells: a survival molecule? J Clin Immunol 18: 256-263 (Pubitemid 28374064)
27. Herndier BG, Werner A, Arnstein P, Abbey NW, Demartis F, Cohen RL, Shuman MA, Levy JA (1994) Characterization of a human Kaposi's sarcoma cell line that induces angiogenic tumors in animals. AIDS 8: 575-581 (Pubitemid 24126114)
28. Herzog CE, Tsokos M, Bates SE, Fojo AT (1993) Increased mdr-1/P-glycoprotein expression after treatment of human colon carcinoma cells with P-glycoprotein antagonists. J Biol Chem 268: 2946-2952 (Pubitemid 23057933)
29. Janneh O, Hartkoorn RC, Jones E, Owen A, Ward SA, Davey R, Back DJ, Khoo SH (2008) Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir. Br J Pharmacol 155: 875-883
30. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S (1998) HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37: 3594-3601 (Pubitemid 28162914)
31. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, Fojo AT, Bates SE (1994) Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 46: 627-638 (Pubitemid 24334752)
32. Maurer T, Ponte M, Leslie K (2007) HIV-associated Kaposi's sarcoma with a high CD4 count and a low viral load. N Engl J Med 357: 1352-1353 (Pubitemid 47481472)
33. Monini P, Sgadari C, Grosso MG, Bellino S, Di Biagio A, Toschi E, Bacigalupo I, Sabbatucci M, Cencioni G, Salvi E, Leone P, Ensoli B (2009) Clinical course of classic Kaposi's sarcoma in HIV-negative patients treated with the HIV protease inhibitor indinavir. AIDS 23: 534-538
34. Mou C, Ganju N, Sridhar KS, Krishan A (1997) Simultaneous quantitation of plasma doxorubicin and prochlorperazine content by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 703: 217-224 (Pubitemid 28011261)
35. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP (2009) Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Crit Rev Oncol Hematol 72: 10-20
36. Nguyen HQ, Magaret AS, Kitahata MM, Van Rompaey SE, Wald A, Casper C (2008) Persistent Kaposi sarcoma in the era of highly active antiretroviral therapy: characterizing the predictors of clinical response. AIDS 22: 937-945 (Pubitemid 351652244)
37. O'Hara AJ, Chugh P, Wang L, Netto EM, Luz E, Harrington WJ, Dezube BJ, Damania B, Dittmer DP (2009) Pre-micro RNA signatures delineate stages of endothelial cell transformation in Kaposi sarcoma. PLoS Pathog 5: e1000389
38. Pellet C, Chevret S, Blum L, Gauville C, Hurault M, Blanchard G, Agbalika F, Lascoux C, Ponscarme D, Morel P, Calvo F, Lebbe C (2001) Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 117: 858-863 (Pubitemid 33001202)
39. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ (2000) Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 14: 1287-1289 (Pubitemid 30420680)
40. Presant CA, Scolaro M, Kennedy P, Blayney DW, Flanagan B, Lisak J, Presant J (1993) Liposomal daunorubicin treatment of HIV-associated Kaposi's sarcoma. Lancet 341: 1242-1243 (Pubitemid 23146931)
41. Sasco AJ, Jaquet A, Boidin E, Ekouevi DK, Thouillot F, Lemabec T, Forstin MA, Renaudier P, N'Dom P, Malvy D, Dabis F (2010) The challenge of AIDS-related malignancies in sub-Saharan Africa. PLoS One 5: e8621
42. Schwartsmann G, Cerski CT, Sander E, Sprinz E, Kronfeld M (1989) P-glycoprotein expression and AIDS-related Kaposi's sarcoma. J Natl Cancer Inst 81: 1755-1756 (Pubitemid 19275918)
43. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B (2002) HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 8: 225-232 (Pubitemid 34250099)
44. Srinivas RV, Middlemas D, Flynn P, Fridland A (1998) Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 42: 3157-3162 (Pubitemid 28553735)
45. Sullivan RJ, Pantanowitz L, Dezube BJ (2009) Targeted therapy for Kaposi sarcoma. BioDrugs 23: 69-75
46. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM (2006) Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5: 219-234 (Pubitemid 43336035)
47. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ (2003) Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS 17: 1092-1094 (Pubitemid 36549726)
48. Vivanco I, Sawyers CL (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501 (Pubitemid 37328931)
49. Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, Weksler B, Bendayan M, Bendayan R (2009) Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 87: 1023-1036